CME Information: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

American Journal of Hematology

Volumn 90, Issue 5, 2015, Pages 446-460

  Hallek, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DASATINIB; EVEROLIMUS; FLUDARABINE; FOSTAMATINIB; IBRUTINIB; IDELALISIB; ISOSORBIDE; LENALIDOMIDE; NAVITOCLAX; OBINUTUZUMAB; OBLIMERSEN; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; VIDARABINE;

ALGORITHM; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; B LYMPHOCYTE; BINET STAGING SYSTEM; BLOOD CELL COUNT; BLOOD SMEAR; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CELL SURVIVAL; CHROMOSOME 17; CHRONIC LYMPHATIC LEUKEMIA; DRUG POTENTIATION; FITNESS; FLOW CYTOMETRY; GENETIC MARKER; HEPATOMEGALY; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHADENOPATHY; MONOCLONAL B CELL LYMPHOCYTOSIS; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RAI STAGING SYSTEM; RISK ASSESSMENT; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; WALDEYER RING; AGED; ANALOGS AND DERIVATIVES; CHROMOSOME DELETION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENE EXPRESSION; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIGENS, CD5; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; GENE EXPRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; VIDARABINE;

EID: 84928253067     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23979     Document Type: Article

References (165)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. [PMC][17237035].
2. National Cancer Institute [Website]. Surveillance Epidemiology and End Results Cancer Statistics review. 2009. Available at: http://seercancergov/statfacts/html/clylhtml. Last accessed March 29 2010.
3. Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma 2006;47:1477-1480.
4. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001. Blood 2006;107:265-276.
5. Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukemia within the European Union. Eur J Haematol 2008;81:253-258.
6. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases. Blood 1999;94:448-454.
7. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
8. Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011;20:246-259.
9. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529.
10. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
11. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010;17:28-40.
12. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.
13. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011;44:47-52.
14. Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-2522.
15. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
16. Seiffert M, Dietrich S, Jethwa A, et al. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:1023-1031.
17. Zenz T, Vollmer D, Trbusek M, et al. TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010;24:2072-2079.
18. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
19. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-1078.
20. Tsukada N, Burger JA, Zvaifler NJ, et al. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002;99:1030-1037.
21. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795-1801.
22. Burger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood 2009;114:3367-3375.
23. Reinart N, Nguyen PH, Boucas J, et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood 2013;121:812-821.
24. Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009:440-449. [CrossRef][10.1182/asheducation-2009.1.440][Mismatch]
25. Hallek M. Signaling the end of chronic lymphocytic leukemia: New frontline treatment strategies. Blood 2013;122:3723-3734.
26. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the national cancer Institute-working group 1996 guidelines. Blood 2008;111:5446-5456.
27. Müller-Hermelink HK, Montserrat E, Catovsky D, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp 127-130.
28. Catovsky D, Ralfkiaer E, Müller-Hermelink HK. T-cell prolymphocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp 195-196.
29. Melo JV, Catovsky D, Galton DAG. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 1986;63:377-387.
30. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. British Journal of Haematology 2005;130:325-332.
31. Rawstron AC, Bennett FL, O'Connor SJM, et al. Monoclonal B-cell lymphocytosis (MBL): A precursor state for chronic lymphocytic leukemia (CLL). N Engl J Med 2008;359:575-583.
32. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378-382.
33. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998;51:364-369.
34. Catovsky D, Müller-Hermelink HK, Montserrat E, et al. B-cell prolymphocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp 131-132.
35. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
36. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-204.
37. Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, editors. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York: Alan R. Liss; 1987. pp 253-264.
38. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998;338:1506-1514.
39. Shustik C, Mick R, Silver R, et al. Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hematol Oncol 1988;6:7-12.
40. Montserrat E, Fontanillas M, Estape J, et al. Chronic lymphocytic leukemia treatment: An interim report of PETHEMA trials. Leuk Lymphoma 1991;5:89-92.
41. CLL trialists' collaborative group. Chemotherapeutic options in chronic lymhocytic leukemia. J Natl Cancer Inst 1999;91:861-868.
42. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol 2011;8:38-47.
43. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014;124:49-62.
44. Cortese D, Sutton LA, Cahill N, et al. On the way towards a 'CLL prognostic index': Focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia 2014;28:710-713.
45. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009;115:363-372.
46. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109:4679-4685.
47. Bottcher S, Hallek M, Ritgen M, et al. The role of minimal residual disease measurements in the therapy for CLL: Is it ready for prime time? Hematol Oncol Clin North Am 2013;27:267-288.
48. Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: Long-term follow-up of a randomized phase III trial of the german CLL study group (GCLLSG). Br J Haematol 2009;144:95-98.
49. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971-2979.
50. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002;119:976-984.
51. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002;87:695-700; discussion 700.
52. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657-2663.
53. Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: Final analysis of CALGB 10101. J Clin Oncol 2010;28:4500-4506.
54. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-Experience on safety and efficacy within a randomized multicenter phase III trial of the german CLL study group (GCLLSG). Leukemia 2004;18:1093-1101.
55. Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30:980-988.
56. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956-964.
57. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559-566.
58. Plunkett W, Gandhi V, Huang P, et al. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993;20:2-12.
59. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
60. Steurer M, Pall G, Richards S, et al. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2006;3:CD004270. [WorldC at]
61. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French cooperative group on CLL [see comments]. Lancet 1996;347:1432-1438.
62. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-2325.
63. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-2729.
64. Ozegowski W, Krebs D. ω[Bis-(β-chloräthyl)-amino-benzimidazolyl-(2)]-propion- bzw. -buttersäuren als potentielle cytostatika. J Prakt Chem B 1963;20:178-186.
65. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4378-4384.
66. Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-174.
67. Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2010;70:261-272.
68. Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012;11:CD008079.
69. Cang S, Mukhi N, Wang K, et al. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012;5:64.
70. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366:2008-2016.
71. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-1331.
72. O'Brien S, Kantarijan H, Thomas D, et al. Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol 2001;19:2165-2170.
73. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-371.
74. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-1755.
75. Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011;152:295-306.
76. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-4402.
77. Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: Final data from the phase 1/2 GAUGUIN study. Blood 2014;124:2196-2202.
78. Österborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leucemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567-1574.
79. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-3897.
80. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99:3554-3561.
81. Stilgenbauer S. Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452-453.
82. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281.
83. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
84. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005;105:4820-4827.
85. Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118:4313-4320.
86. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:88-96.
87. Pogue SL, Kurosaki T, Bolen J, et al. B cell antigen receptor-induced activation of akt promotes B cell survival and is dependent on syk kinase. J Immunol 2000;165:1300-1306.
88. Gobessi S, Laurenti L, Longo PG, et al. Inhibition of constitutive and BCR-induced syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009;23:686-697.
89. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of syk with fostamatinib disodium has significant clinical activity in non-hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
90. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3:317-330.
91. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-3612.
92. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390-3397.
93. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-6296.
94. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94.
95. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
96. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370:2286-2294.
97. Veldurthy A, Patz M, Hagist S, et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008;112:1443-1452.
98. McCaig AM, Cosimo E, Leach MT, et al. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 2011;153:199-211.
99. Tromp JM, Geest CR, Breij EC, et al. Tipping the noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res 2012;18:487-498.
100. Amrein L, Hernandez TA, Ferrario C, et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 2008;143:698-706.
101. Kuckertz M, Patz M, Veldurthy A, et al. Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. Onkologie 2012;35:420-426.
102. Harr MW, Caimi PF, McColl KS, et al. Inhibition of lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ 2010;17:1381-1391.
103. Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977-2986.
104. Chao DT, Korsmeyer SJ. BCL-2 family: Regulators of cell death. Annu Rev Immunol 1998;16:395-419.
105. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984;226:1097-1099.
106. Balakrishnan K, Burger JA, Wierda WG, et al. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009;113:149-153.
107. Castro JE, Loria OJ, Aguillon RA, et al. A phase II, open label study of at-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens. ASH Annual Meeting Abstracts 2007;110:3119.
108. Castro JE, Olivier LJ, Robier AA, et al. A phase II, open label study of at-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 2006;108:2838.
109. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
110. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-496.
111. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-208.
112. Seymour JF, Davids MS, Pagel JM, et al. ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control. J Clin Oncol 2014;32:abstract 7015.
113. Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85-88.
114. Moutouh-de Parseval LA, Weiss L, DeLap RJ, et al. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047.
115. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 2006;24:5343-5349.
116. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-5297.
117. Chanan-Khan AA, Czuczman MS, Padmanabhan S, et al. Clinical efficacy of lenalidomide in Fludarabine-refractory chronic lymphocytic leukemia patients. ASH Annual Meeting Abstracts 2007;110:3108.
118. Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013;31:584-591.
119. Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010;24:1972-1975.
120. Flinn IW, Berdeja JG, Waselenko JK, et al. Preliminary results from a phase I/II study of fludarabine, rituximab, and lenalidomide in untreated patients with chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2010;116:2461.
121. Egle A, Steurer M, Melchardt T, et al. The REVLIRIT CLL5 AGMT Study-A phase I/II trial combining fludarabine/rituximab with escalating doses of lenalidomide followed by rituximab/lenalidomide in untreated chronic lymphocytic leukemia (CLL): Results of a planned interim analysis. ASH Annual Meeting Abstracts 2009;114:3453.
122. Blum KA, Jones JA, Andritsos L, et al. Phase 1 trial of flavopiridol and lenalidomide in patients with previously treated chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2010;116:2472.
123. Badoux X, O'Brien S, Wierda WG, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: Initial results of a phase II trial. ASH Annual Meeting Abstracts 2010;116:2464.
124. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12:5165-5173.
125. Decker T, Sandherr M, Goetze K, et al. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2009;88:221-227.
126. Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116:2201-2207.
127. Bellosillo B, Villamor N, Colomer D, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999;94:2836-2843.
128. Hallek M, Eichhorst BF. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J 2004;5:S20-S30.
129. Montillo M, Tedeschi A, O'Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003;97:114-120.
130. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-891.
131. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 2007;25:793-798.
132. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial. Lancet 2007;370:230-239.
133. Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: Report of a prospective, multicenter, randomized trial of the polish adult leukemia group (PALG CLL2). Blood 2006;108:473-479.
134. di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800-809.
135. Schulz H, Klein SH, Rehwald U, et al. Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-3120.
136. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from cancer and leukemia group B 9712 (CALGB 9712). Blood 2003;101:6-14.
137. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
138. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-980.
139. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-1765.
140. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:498-503.
141. Parikh SA, Keating MJ, O'Brien S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011;118:2062-2068.
142. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-4584.
143. Reynolds C, Di Bella N, Lyons RM, et al. A phase III trial of fludarabine, cyclophosphamide, and rituximab vs. Pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012;30:1232-1240.
144. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the german chronic lymphocytic leukemia study group. J Clin Oncol 2011;29:3559-3566.
145. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the german chronic lymphocytic leukemia study group. J Clin Oncol 2012;30:3209-3216.
146. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the german CLL study group (GCLLSG) (CLL10 study). Blood 2014;124:abstract 19.
147. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101-1110.
148. Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): Final response analysis of an Open-label phase II study. ASH Annual Meeting Abstracts 2010;116:697.
149. Foa R, Ciolli SD, Raimondo F, et al. A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the first interim analysis. ASH Annual Meeting Abstracts 2010;116:2462.
150. Goede V, Fischer K, Busch R, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: Results of the CLL11 (BO21004) safety run-in. Leukemia 2013;27:1172-1174.
151. Hillmen P, Robak T, Janssens A, et al. Ofatumumab+Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood 2013;122:528.
152. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245-2247.
153. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. J Clin Oncol 2005;23:7024-7031.
154. Lepretre S, Aurran T, Mahe B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012;119:5104-5110.
155. Hallek M. FCA: Forget chemoimmunotherapy with alemtuzumab? Blood 2012;119:5059-5060.
156. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: A randomised phase 3 trial. Lancet Oncol 2011;12:1204-1213.
157. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413-3415.
158. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997-1007.
159. Borge M, Almejun MB, Podaza E, et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica 2015;100:e140-e142.
160. Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014;123:1957-1960.
161. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study. Lancet Oncol 2014;15:1090-1099.
162. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older patients. J Clin Oncol 1998;16:1582-1587.
163. Dreger P, Schetelig J, Andersen N, et al. Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents? Blood 2014;124:3841-3849.
164. Hallek M. Chronic lymphocytic leukemia: 2013 Update on diagnosis, risk stratification and treatment. Am J Hematol 2013;88:803-816.
165. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood 2015;125:2062-2067.